ArticleWorld journal of surgical oncology2026
In silico analysis of driver genes in squamous cell carcinoma of the cervix: insights into their biological functions, prognosis, immune infiltration, and therapy.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer is the fourth most common cancer affecting the female reproductive system worldwide. Although several studies have reported recurrent mutations in cervical squamous cell carcinoma (SCC), a comprehensive understanding of the clinically relevant driver genes remains limited. Unlike previous single-cohort or frequency-based reports, this study integrates four independent cervical squamous cell carcinoma (SCC) cohorts with network-based analysis, multiendpoint survival assessment, and drug-gene interaction to prioritize functionally and clinically relevant driver hub genes. MATERIALS AND
methodsIn this study, we performed a genomic analysis of a cohort of 4 squamous cell carcinomas of the cervix (SCCs), consisting of 467 samples, to identify driver genes and their clinical significance. Key pathways and biological functions affected were tested by functional enrichment analysis. The Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) and CytoHubba tools were used to construct a protein‒protein interaction network (PPIN) and identify the hub genes. Additional analyses included enrichment assessment of cancer hallmarks, survival evaluation, immune cell infiltration profiling, and drug‒gene interaction studies.
resultsOur analysis revealed 9,749,109 mutations across 44 driver genes. PIK3CA, KMT2C, KMT2D, FBXW7, FAT1, EP300, TP53, NOTCH1, STK11, and CASP8 were the top 10 mutated genes. PIK3CA, NOTCH1, PTEN, KRAS, ERBB2, TP53, ARID1A, EP300, STK11, and FBXW7 emerged as the top 10 hub genes according to the results of the PPIN and Cytohubba analyses. In addition, we observed significant differences in T helper cell type 2, natural killer cell, dendritic cell, and gamma delta T-cell composition in samples with hub gene mutations. Prioritization analysis of drug and hub gene interactions revealed 112 clinically relevant compounds, especially HER2-directed therapies (trastuzumab), PI3K inhibitors (alpelisib), and mTOR inhibitors (everolimus).
conclusionCollectively, our analysis describes the driver genes and mutation characteristics in SCC. The multi-cohort and network-based framework employed in this study identifies candidate hub genes that warrant further clinical investigation in cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.